Pfizer(US:PFE) Mei Ri Jing Ji Xin Wen·2025-10-27 14:13Core Insights - The article discusses the significant growth of foreign investment in R&D in China, highlighting a 91.5% increase in R&D spending by foreign-invested industrial enterprises over the past decade, and the acceleration of foreign pharmaceutical companies like Pfizer in the Chinese market [1][2]. Policy Acceleration - Pfizer's Beijing R&D center aims to introduce global innovative drugs and vaccines at three times the previous rate, with a target of over 60 new drug approvals by 2030, having already surpassed half of this goal [2]. - The center has benefited from expedited drug review processes, achieving clinical trial approvals in 30 days instead of the traditional 60 days, significantly speeding up patient enrollment [2][3]. Local Enterprise Rise - The Chinese biopharmaceutical industry has evolved from a follower to a participant and even a leader in some areas, with local companies increasingly demonstrating innovation capabilities [4]. - The industry is at a critical juncture, focusing on how domestic innovations can benefit global patients, which presents both challenges and long-term goals [4][5]. Future Competition - The next decade is expected to be pivotal for the biopharmaceutical sector, with digital and AI technologies driving rapid changes and creating both opportunities and challenges for the industry [6][7]. - The application of AI in drug discovery and development is seen as a significant area for improvement, with the potential to enhance efficiency and success rates in clinical trials [6][7].